Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

CYTOKINETICS, INC. (CYTK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

CYTOKINETICS INC : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/10/2018 | 10:18pm CEST

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

As previously disclosed in the Current Report on Form 8-K filed on October 27, 2017, Cytokinetics, Incorporated (the "Company") entered into a Second Amendment (the "Amendment") to that certain loan and security agreement (the "Original Loan Agreement") dated October 19,2015 with Oxford Finance LLC ("Oxford"), as the collateral agent and a lenders party thereto.

On August 8, 2018, following the satisfaction of certain conditions related to Phase 2 data for reldesemtiv in spinal muscular atrophy specified in the Amendment, the Company drew an additional $10.0 million.

In connection with Term Loan C, the Company issued to the Lenders warrants exercisable for 42,253 shares of the Company's common stock (the "Warrants"). The Warrants are exercisable in whole or in part, immediately, and have a per share price of $7.10, which was calculated based on the methodology provided in the Agreement.

The foregoing is only a summary of the material terms of the Agreement and the Warrants, and does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement and the Warrants.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth under Item 2.03 above that relates to the issuance of the Warrants is hereby incorporated by reference into Item 3.02.

The Warrants described in Item 2.03 above were offered and sold in reliance upon the exemption from registration provided by Section 4(a)(2) under the Securities Act of 1933, as amended (the "Securities Act"). The Warrants contain representations to support the Company's reasonable belief that each of the recipients of such securities had access to information concerning the Company's operations and financial condition, that each such recipient is acquiring the securities for its own account and not with a view to the distribution thereof, and that each such recipient is an "accredited investor" as defined by Rule 501 promulgated under the Securities Act.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
10/18Cytokinetics to Announce Third Quarter Results on November 1, 2018
GL
10/16CYTOKINETICS : Unveils Expanded Development Pipeline and Provides Key Updates on..
PU
10/16CYTOKINETICS INC : Other Events (form 8-K)
AQ
10/16Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates ..
GL
10/10CYTOKINETICS : And astellas provide updates regarding collaborative skeletal mus..
AQ
10/06CYTOKINETICS : and Astellas Provide Updates Regarding Collaborative Skeletal Mus..
AQ
10/05CYTOKINETICS INC : Other Events (form 8-K)
AQ
10/05ASTELLAS PHARMA : Cytokinetics and Astellas Provide Updates Regarding Collaborat..
AQ
10/03CYTOKINETICS : to Host R&D Day on October 16, 2018
AQ
10/02Cytokinetics to Host R&D Day on October 16, 2018
GL
More news
News from SeekingAlpha
10/16Cytokinetics debuts two new pipeline candidates at R&D Day 
10/12Key events next week - healthcare 
10/07WEEK 41 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
09/24Cardiac device makers in the green on positive data at industry conference 
09/24WEEK 39 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
Financials ($)
Sales 2018 17,6 M
EBIT 2018 -97,9 M
Net income 2018 -113 M
Finance 2018 155 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 13,7x
EV / Sales 2019 5,84x
Capitalization 397 M
Chart CYTOKINETICS, INC.
Duration : Period :
Cytokinetics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYTOKINETICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 13,8 $
Spread / Average Target 91%
EPS Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Ching Jaw Chief Financial Officer & Senior Vice President
Andrew A. Wolff Chief Medical Officer & Senior Vice President
John Tannahill Henderson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.-6.50%425
GILEAD SCIENCES1.59%96 150
VERTEX PHARMACEUTICALS20.99%45 720
REGENERON PHARMACEUTICALS2.18%41 951
NEUROCRINE BIOSCIENCES, INC.41.84%10 366
SAREPTA THERAPEUTICS INC136.05%9 222